Sugi Predict

Sugi Predict / Compounds / SCHEMBL8084

SCHEMBL8084

SCHEMBL8084

O=c1c(-c2ccccc2)c(CSc2ncnc3[nH]cnc23)oc2ccccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ RXFP1 Q9HBX9 7/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ NPSR1 Q6W5P4 5/20 0.39
▸ TSHR P16473 5/20 0.39
▸ HPGD P15428 5/20 0.39
▸ MAPK1 P28482 2/20 0.39
▸ CREBBP Q92793 2/20 0.39
▸ PIK3CG P48736 2/20 0.38
▸ PIK3CD O00329 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ PPARG P37231 5/20 0.38
▸ NCOA1 Q15788 5/20 0.38
▸ ALDH1A1 P00352 5/20 0.38
▸ NCOA2 Q15596 3/20 0.37
▸ LMNA P02545 1/20 0.37
▸ TP53 P04637 1/20 0.37
▸ MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30013089 1.00 CA1 (0.42) CA1CA2RXFP1KMT2AMEN1
SCHEMBL9452 0.90 CDC7 (0.41) CA1CA2RXFP1KMT2AMEN1
SCHEMBL29651571 0.90 CDC7 (0.41) CA1CA2RXFP1KMT2AMEN1
SCHEMBL16783413 0.86 CDC7 (0.40) RXFP1KMT2AMEN1NPSR1HPGD
SCHEMBL20748577 0.82 CA1 (0.37) CA1CA2KMT2AHPGDMAPK1
SCHEMBL8526 0.81 CA1 (0.43) CA1CA2KMT2ATSHRHPGD
SCHEMBL30670887 0.81 CA1 (0.43) CA1CA2KMT2ATSHRHPGD
SCHEMBL8738 0.81 CDC7 (0.40) CA1CA2RXFP1KMT2AMEN1
SCHEMBL15689089 0.79 PIK3CD (0.41) CA1CA2TSHRHPGDMAPK1
SCHEMBL16783496 0.76 HPGD (0.38) RXFP1KMT2AMEN1NPSR1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4292596-A1 METHOD AND COMBINATION FOR TREATING TUMORS Curon Biopharmaceutical (Shanghai) Co., Limited (CN) 2023-12-20 — — EP claimed
CN-117222413-A Methods and combinations for treating tumors 同润生物医药(上海)有限公司 2023-12-12 — — CN claimed
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 — — US claimed
EP-2496567-B1 NOVEL BENZOPYRAN KINASE MODULATORS RHIZEN PHARMACEUTICALS S A (CH) 2017-07-12 — — EP claimed
US-20160318890-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2016-11-03 — — US claimed
US-9421209-B2 Kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2016-08-23 — — US claimed
US-20150174131-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2015-06-25 — — US claimed
US-9018375-B2 Substituted chromenes as kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2015-04-28 — — US claimed
US-20140080827-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2014-03-20 — — US claimed
US-8642607-B2 4H-chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2014-02-04 — — US claimed
EP-2496567-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2012-09-12 — — EP claimed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 — — US claimed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US claimed
WO-2011055215-A2 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-05-12 — — WO claimed
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 — — US disclosed
US-20240139198-A1 METHOD AND COMBINATION FOR TREATING TUMORS CURON BIOPHARMACEUTICAL (SHANGHAI) CO., LIMITED (CN) 2024-05-02 — — US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US disclosed
WO-2011055215-A2 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-05-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150174131-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB CA1 4615/4885CA2 3756/4885RXFP1 4015/4885
US-20240360095-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB CA1 4615/4885CA2 3756/4885RXFP1 4015/4885
US-20140080827-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB CA1 4615/4885CA2 3756/4885RXFP1 4015/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB CA1 4615/4885CA2 3756/4885RXFP1 4015/4885
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB CA1 4615/4885CA2 3756/4885RXFP1 4015/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A CA1 4543/4885CA2 3288/4885RXFP1 1552/4885
US-20160318890-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB CA1 4615/4885CA2 3756/4885RXFP1 4015/4885
US-20240139198-A1 METHOD AND COMBINATION FOR TREATING TUMORS PDCD1, PDCD1LG2, CD274 CA1 1456/4885CA2 875/4885RXFP1 2610/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB CA1 4615/4885CA2 3756/4885RXFP1 4015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.